SUBSCRIBE
SUBSCRIBE

Johnson & Johnson Family of Companies

NEWS
Deals
Johnson & Johnson Deal Could Break Up Actelion Into Two Companies
January 3, 2017
 · 
1 min read
Bay Area's Depomed Craters as New CEO, Directors are Named in Deal with Activist Investor
Deals
Battle for Actelion: Sanofi is Out, Johnson & Johnson is Back In
December 22, 2016
 · 
3 min read
Bay Area's Depomed Craters as New CEO, Directors are Named in Deal with Activist Investor
Deals
Digging Deeper on Why Johnson & Johnson Abandoned the Actelion Acquisition
December 15, 2016
 · 
3 min read
Policy
Thousands of Men Take on Johnson & Johnson for Giving Them Man Boobs
December 15, 2016
 · 
1 min read
For Sale: Pfizer's $3.4 Billion Consumer Healthcare Business
Drug Development
Pfizer’s Xtandi Flunks Late-Stage Study Against Johnson & Johnson’s Zytiga
December 15, 2016
 · 
2 min read
It's Finally Happening: Johnson & Johnson Pays $30 Billion for Actelion, Will Spin Off R&D Unit With $1 Billion Cash
Deals
Johnson & Johnson Walks and Sanofi Steps in to Woo Actelion
December 14, 2016
 · 
3 min read
How Johnson & Johnson Alum Helped AxoGen Survive Despite Not Having Millions in the Bank
December 12, 2016
 · 
1 min read
Deals
Why Big Pharma Johnson & Johnson is Getting Into Startups
December 8, 2016
 · 
1 min read
Genetown
Johnson & Johnson Woos Billionaire Doctors Who Don’t Need Cash In Actelion Bid
December 6, 2016
 · 
1 min read
Load More
AWARDS
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Press Releases
European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
December 22, 2025
 · 
14 min read
Press Releases
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
December 19, 2025
 · 
6 min read
Press Releases
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
December 18, 2025
 · 
33 min read
Press Releases
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results - December 15, 2025
December 16, 2025
 · 
1 min read
Press Releases
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors
December 16, 2025
 · 
4 min read
Press Releases
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
December 15, 2025
 · 
20 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
18 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
28 min read
Press Releases
Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 9, 2025
 · 
1 min read
Press Releases
Earlier use of CARVYKTI®▼ (ciltacabtagene autoleucel) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
December 8, 2025
 · 
15 min read
Load More